MedTrace Logo

Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis

NCT04899180 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-08-07

No results posted yet for this study

Summary

The purpose of this study is to determine the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among patients with moderate and severe aortic stenosis in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).

Conditions

  • Aortic Stenosis
  • Transthyretin Amyloidosis
  • Transthyretin Amyloid Cardiomyopathy
  • Transthyretin Cardiac Amyloidosis

Interventions

DRUG

99mTc-PYP

Radioisotope used by SPECT/CT imaging

Sponsors & Collaborators

Principal Investigators

  • Omar F Abou Ezzeddine, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-14
Primary Completion
2024-01-05
Completion
2024-01-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04899180 on ClinicalTrials.gov